Published on 17 Jan 2024 on GuruFocus.com via Yahoo Finance
BridgeBio Pharma Inc Director Hannah Valantine Sells 2,915 Shares
On January 16, 2024, Director Hannah Valantine sold 2,915 shares of BridgeBio Pharma Inc (NASDAQ:BBIO), as reported in a recent SEC filing. The transaction was executed at an average price of $37.97 per share, resulting in a total sale amount of approximately $110,652.55.
BridgeBio Pharma Inc is a biotechnology company focused on discovering, developing, and delivering breakthrough medicines for genetic diseases. The company has a diverse portfolio of drug candidates targeting various illnesses, with an emphasis on genetic dermatology, oncology, and cardiology.
Warning! GuruFocus has detected 5 Warning Signs with BBIO.